Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics, Inc. (NASDAQ:CGEM), filed a Form 4 on September 10, 2026, reporting a stock option exercise and a sale of common stock executed on September 8, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Michaelson acquired 4,000 shares of common stock via a stock option exercise (transaction code M) at an exercise price of $4.30 per share on September 8, 2026.
  • Share sale: 8,000 shares of common stock were disposed of (transaction code S) at a weighted average price of $21.57, with individual sale prices ranging from $21.31 to $21.83.
  • 10b5-1 plan: According to the filing, the sale was effected pursuant to a plan established under Rule 10b5-1 on August 7, 2025.
  • Remaining ownership: Following the reported transactions, Michaelson directly beneficially owns 158,844 shares of common stock.
  • Derivative securities: Michaelson retains 78,987 stock options (right to buy) with an exercise price of $4.30 and an expiration date of October 28, 2030, held directly.

Michaelson's September 2026 Transactions at Cullinan Therapeutics

According to the filing, Jennifer Michaelson, serving as Chief Scientific Officer of Cullinan Therapeutics, Inc., reported two non-derivative transactions on September 8, 2026. First, she exercised a stock option to acquire 4,000 shares of common stock at $4.30 per share, bringing her directly held position to 166,844 shares following that transaction.

In the same session, Michaelson disposed of 8,000 shares of common stock at a weighted average sale price of $21.57. The filing discloses that the shares were sold in multiple transactions at prices ranging from $21.31 to $21.83, and that full details of the number of shares sold at each separate price are available upon request from the issuer, any shareholder, or SEC staff. After this disposal, her directly held beneficial ownership stood at 158,844 shares of common stock.

The filing notes that the sale was carried out under a trading plan established on August 7, 2025, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Separately, in Table II, the filing records the exercise of 4,000 stock options, leaving Michaelson with 78,987 directly held stock options with an exercise price of $4.30 and an expiration date of October 28, 2030. The filing states that 25% of those options vested on July 4, 2020, with the remainder vesting in 36 equal monthly installments thereafter. The Form 4 was signed by Jacquelyn Sumer as Attorney-in-Fact on September 10, 2026.

What Was Disclosed

Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson reported an option exercise of 4,000 shares at $4.30 and a sale of 8,000 shares at a weighted average of $21.57, leaving her with 158,844 directly held shares and 78,987 remaining stock options.